We don’t follow footsteps. We create the path.

Scientist working in Spark's labs in Philadelphia

News & events

Spark Therapeutics Announces Preliminary Data on SPK-8016 Preliminary data presented on Phase 1/2 clinical trial of investigational SPK-8016 in hemophilia A at EAHAD 2021

Read More read more

Spark Therapeutics Announces First Participant Dosed in Phase 1/2 trial of SPK-3006 First participant dosed in the RESOLUTESM trial, a Phase 1/2 dose-escalation study of investigational SPK-3006 for late-onset Pompe disease

Read More read more

Spark Therapeutics Announces Updated Data on SPK-8011 Updated data presented on Phase 1/2 clinical trial of investigational SPK-8011 in hemophilia A at ISTH 2020

Read More read more

Get our news alerts delivered straight to your inbox

Subscribe Now

We don’t follow footsteps. We create the path.

Our mission at Spark Therapeutics is to challenge the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable—until now. We have built a fully integrated company, combining our proprietary adeno-associated viral (AAV) gene therapy platform with excellence in R&D, manufacturing and commercial operations. Find out more about how we strive to turn genes into medicines for patients with inherited diseases, including inherited retinal diseases (IRDs), liver-directed diseases such as hemophilia, and neurodegenerative diseases.

Learn More